JP2007536911A - 標的抗原 - Google Patents

標的抗原 Download PDF

Info

Publication number
JP2007536911A
JP2007536911A JP2006547589A JP2006547589A JP2007536911A JP 2007536911 A JP2007536911 A JP 2007536911A JP 2006547589 A JP2006547589 A JP 2006547589A JP 2006547589 A JP2006547589 A JP 2006547589A JP 2007536911 A JP2007536911 A JP 2007536911A
Authority
JP
Japan
Prior art keywords
sequence
antigen
amino acid
peptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006547589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536911A5 (enExample
Inventor
ロバート アーガー，エイ
サルハ，ダニエレ
ガリチャン，スコット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANOFI PASTEUR Inc
Original Assignee
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOFI PASTEUR Inc filed Critical SANOFI PASTEUR Inc
Publication of JP2007536911A publication Critical patent/JP2007536911A/ja
Publication of JP2007536911A5 publication Critical patent/JP2007536911A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006547589A 2003-12-31 2004-12-30 標的抗原 Abandoned JP2007536911A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53372803P 2003-12-31 2003-12-31
PCT/US2004/044023 WO2005066203A2 (en) 2003-12-31 2004-12-30 Targeted immunogens

Publications (2)

Publication Number Publication Date
JP2007536911A true JP2007536911A (ja) 2007-12-20
JP2007536911A5 JP2007536911A5 (enExample) 2008-06-26

Family

ID=34748948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547589A Abandoned JP2007536911A (ja) 2003-12-31 2004-12-30 標的抗原

Country Status (12)

Country Link
US (1) US20060002946A1 (enExample)
EP (1) EP1699492A2 (enExample)
JP (1) JP2007536911A (enExample)
KR (1) KR20060129353A (enExample)
CN (1) CN1921889A (enExample)
AU (1) AU2004312548A1 (enExample)
BR (1) BRPI0418273A (enExample)
CA (1) CA2552251A1 (enExample)
IL (1) IL176603A0 (enExample)
MX (1) MXPA06007574A (enExample)
WO (1) WO2005066203A2 (enExample)
ZA (1) ZA200605304B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511571A (ja) * 2015-02-18 2018-04-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 標的細胞に対するｔ細胞の細胞傷害性の特異的誘導のためのイムノコンジュゲート

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
CA2984629C (en) 2015-05-07 2024-06-18 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391791T1 (de) * 2000-08-25 2008-04-15 Aventis Pharma Inc Membran penetrierende peptide und deren anwendungen
CA2477429A1 (en) * 2002-01-29 2003-08-07 Robert A. Uger Targeted immunogens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511571A (ja) * 2015-02-18 2018-04-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 標的細胞に対するｔ細胞の細胞傷害性の特異的誘導のためのイムノコンジュゲート

Also Published As

Publication number Publication date
WO2005066203A2 (en) 2005-07-21
IL176603A0 (en) 2006-10-31
US20060002946A1 (en) 2006-01-05
CN1921889A (zh) 2007-02-28
WO2005066203A3 (en) 2005-09-01
BRPI0418273A (pt) 2007-05-02
EP1699492A2 (en) 2006-09-13
MXPA06007574A (es) 2007-04-17
KR20060129353A (ko) 2006-12-15
AU2004312548A1 (en) 2005-07-21
CA2552251A1 (en) 2005-07-21
ZA200605304B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
JP5156882B2 (ja) Ｈｌａ−ａ２腫瘍関連抗原ペプチドおよび組成物
JP2021113218A (ja) 新生物ワクチン用製剤
AU2011200127B2 (en) Multi-antigen vectors for melanoma
CA2772551A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20110311543A1 (en) Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer
CN1910198B (zh) 用于预防和/或治疗癌症的肿瘤抗原
US20130101625A1 (en) Modified cea nucleic acid and expression vectors
US20030113919A1 (en) Immunogenic targets for melanoma
EP1864691A1 (en) Modified CEA nucleic acid and expression vectors
US20040002455A1 (en) Targeted immunogens
US20030148973A1 (en) MAGE-A1 peptides for treating or preventing cancer
US20060002946A1 (en) Targeted immunogens
KR101162970B1 (ko) 변형된 ｃｅａ/ｂ7 벡터
AU2003216119A1 (en) Targeted immunogens
CN1878566B (zh) 用于黑素瘤的多抗原载体
RU2774820C2 (ru) Основанные на hla способы и композиции и их применение
US20090156519A1 (en) Modified KSA and Uses Thereof
MXPA06002477A (en) Multi-antigen vectors for melanoma
AU2011224126A1 (en) Tumor antigens BFA5 for prevention and/or treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071217

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20081010